Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Undisclosed hematological tumor antigen (HC111)
- Molecular classification
- Receptor, Cell surface protein
01
Overview
- Other names
- Undisclosed cancer cell surface antigen recognized by the HC111 CARHC111 target antigenProprietary hematological tumor antigen
02
Biological functions
Cell-cell signalingTumor cell survivalOther
03
Disease associations
CancerHematological NeoplasmsLeukemiaLymphoma
04
Safety considerations
On-target off-tumor toxicityCytokine release syndrome (low risk)Immune effector cell-associated neurotoxicity syndrome (low risk)
05
Interacting drugs
HC111 (iPSC-CAR-NK)
06
Biomarkers
Target antigen expression on tumor cells
Beyond the preview
Go deeper on Undisclosed hematological tumor antigen (HC111).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Undisclosed hematological tumor antigen (HC111).